A potential limitation of the concept described here, to use decitabine-mediated upregulation on ovarian cancer cells to enable targeting by CSPG4-CAR-T cells, is posed by the tumor promoting properties of CSPG4, which might additionally foster the growth of decitabine-treated tumor cells [7]. Here, CSPG4 is linked to ovarian cancer.